Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters. 2016

Pavithra Viswanath, and Chloe Najac, and Jose L Izquierdo-Garcia, and Aleksandr Pankov, and Chibo Hong, and Pia Eriksson, and Joseph F Costello, and Russell O Pieper, and Sabrina M Ronen
Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94143, USA.

Mutations in isocitrate dehydrogenase 1 (IDH1) are characteristic of low-grade gliomas. We recently showed that mutant IDH1 cells reprogram cellular metabolism by down-regulating pyruvate dehydrogenase (PDH) activity. Reduced pyruvate metabolism via PDH could lead to increased pyruvate conversion to lactate. The goal of this study was therefore to investigate the impact of the IDH1 mutation on the pyruvate-to-lactate flux. We used 13C magnetic resonance spectroscopy and compared the conversion of hyperpolarized [1-13C]-pyruvate to [1-13C]-lactate in immortalized normal human astrocytes expressing mutant or wild-type IDH1 (NHAIDHmut and NHAIDHwt). Our results indicate that hyperpolarized lactate production is reduced in NHAIDHmut cells compared to NHAIDHwt. This reduction was associated with lower expression of the monocarboxylate transporters MCT1 and MCT4 in NHAIDHmut cells. Furthermore, hyperpolarized lactate production was comparable in lysates of NHAIDHmut and NHAIDHwt cells, wherein MCTs do not impact hyperpolarized pyruvate delivery and lactate production. Collectively, our findings indicated that lower MCT expression was a key contributor to lower hyperpolarized lactate production in NHAIDHmut cells. The SLC16A3 (MCT4) promoter but not SLC16A1 (MCT1) promoter was hypermethylated in NHAIDHmut cells, pointing to possibly different mechanisms mediating reduced MCT expression. Finally analysis of low-grade glioma patient biopsy data from The Cancer Genome Atlas revealed that MCT1 and MCT4 expression was significantly reduced in mutant IDH1 tumors compared to wild-type. Taken together, our study shows that reduced MCT expression is part of the metabolic reprogramming of mutant IDH1 gliomas. This finding could impact treatment and has important implications for metabolic imaging of mutant IDH1 gliomas.

UI MeSH Term Description Entries
D007521 Isocitrate Dehydrogenase An enzyme of the oxidoreductase class that catalyzes the conversion of isocitrate and NAD+ to yield 2-ketoglutarate, carbon dioxide, and NADH. It occurs in cell mitochondria. The enzyme requires Mg2+, Mn2+; it is activated by ADP, citrate, and Ca2+, and inhibited by NADH, NADPH, and ATP. The reaction is the key rate-limiting step of the citric acid (tricarboxylic) cycle. (From Dorland, 27th ed) (The NADP+ enzyme is EC 1.1.1.42.) EC 1.1.1.41. NAD Isocitrate Dehydrogenase,Isocitrate Dehydrogenase (NAD+),Isocitrate Dehydrogenase-I,Dehydrogenase, Isocitrate,Dehydrogenase, NAD Isocitrate,Isocitrate Dehydrogenase I,Isocitrate Dehydrogenase, NAD
D009124 Muscle Proteins The protein constituents of muscle, the major ones being ACTINS and MYOSINS. More than a dozen accessory proteins exist including TROPONIN; TROPOMYOSIN; and DYSTROPHIN. Muscle Protein,Protein, Muscle,Proteins, Muscle
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D005910 Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) Glial Cell Tumors,Malignant Glioma,Mixed Glioma,Glial Cell Tumor,Glioma, Malignant,Glioma, Mixed,Gliomas,Gliomas, Malignant,Gliomas, Mixed,Malignant Gliomas,Mixed Gliomas,Tumor, Glial Cell,Tumors, Glial Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D027501 Monocarboxylic Acid Transporters A family of proteins involved in the transport of monocarboxylic acids such as LACTIC ACID and PYRUVIC ACID across cellular membranes. Monocarboxylic Acid Transport Proteins,Pyr Translocator,Pyruvate Carrier,Pyruvate Transport Protein,Pyruvate Transport Proteins,Pyruvate Transporter,Erythrocyte Lactate Transporter,Erythrocyte Lactate Transporters,Lactate Translocase,Lactate Transport Protein,Lactate Transport Proteins,Lactate Transporter,MCT Proteins,Monocarboxylate Translocator,Monocarboxylic Acid Transport Protein,Acid Transporters, Monocarboxylic,Carrier, Pyruvate,Lactate Transporter, Erythrocyte,Lactate Transporters, Erythrocyte,Protein, Pyruvate Transport,Translocase, Lactate,Translocator, Monocarboxylate,Translocator, Pyr,Transport Protein, Lactate,Transport Protein, Pyruvate,Transport Proteins, Lactate,Transport Proteins, Pyruvate,Transporter, Erythrocyte Lactate,Transporter, Lactate,Transporter, Pyruvate,Transporters, Erythrocyte Lactate,Transporters, Monocarboxylic Acid
D027981 Symporters Membrane transporters that co-transport two or more dissimilar molecules in the same direction across a membrane. Usually the transport of one ion or molecule is against its electrochemical gradient and is "powered" by the movement of another ion or molecule with its electrochemical gradient. Co-Transporter,Co-Transporters,Symporter,Co Transporter,Co Transporters

Related Publications

Pavithra Viswanath, and Chloe Najac, and Jose L Izquierdo-Garcia, and Aleksandr Pankov, and Chibo Hong, and Pia Eriksson, and Joseph F Costello, and Russell O Pieper, and Sabrina M Ronen
January 2017, Advances in neurobiology,
Pavithra Viswanath, and Chloe Najac, and Jose L Izquierdo-Garcia, and Aleksandr Pankov, and Chibo Hong, and Pia Eriksson, and Joseph F Costello, and Russell O Pieper, and Sabrina M Ronen
February 2015, Obesity reviews : an official journal of the International Association for the Study of Obesity,
Pavithra Viswanath, and Chloe Najac, and Jose L Izquierdo-Garcia, and Aleksandr Pankov, and Chibo Hong, and Pia Eriksson, and Joseph F Costello, and Russell O Pieper, and Sabrina M Ronen
January 2022, Analytical cellular pathology (Amsterdam),
Pavithra Viswanath, and Chloe Najac, and Jose L Izquierdo-Garcia, and Aleksandr Pankov, and Chibo Hong, and Pia Eriksson, and Joseph F Costello, and Russell O Pieper, and Sabrina M Ronen
February 2005, American journal of physiology. Cell physiology,
Pavithra Viswanath, and Chloe Najac, and Jose L Izquierdo-Garcia, and Aleksandr Pankov, and Chibo Hong, and Pia Eriksson, and Joseph F Costello, and Russell O Pieper, and Sabrina M Ronen
December 2010, Clinical & experimental metastasis,
Pavithra Viswanath, and Chloe Najac, and Jose L Izquierdo-Garcia, and Aleksandr Pankov, and Chibo Hong, and Pia Eriksson, and Joseph F Costello, and Russell O Pieper, and Sabrina M Ronen
October 2016, Journal of neuro-oncology,
Pavithra Viswanath, and Chloe Najac, and Jose L Izquierdo-Garcia, and Aleksandr Pankov, and Chibo Hong, and Pia Eriksson, and Joseph F Costello, and Russell O Pieper, and Sabrina M Ronen
September 2010, British journal of cancer,
Pavithra Viswanath, and Chloe Najac, and Jose L Izquierdo-Garcia, and Aleksandr Pankov, and Chibo Hong, and Pia Eriksson, and Joseph F Costello, and Russell O Pieper, and Sabrina M Ronen
November 2007, Breast cancer research and treatment,
Pavithra Viswanath, and Chloe Najac, and Jose L Izquierdo-Garcia, and Aleksandr Pankov, and Chibo Hong, and Pia Eriksson, and Joseph F Costello, and Russell O Pieper, and Sabrina M Ronen
November 2011, Blood,
Pavithra Viswanath, and Chloe Najac, and Jose L Izquierdo-Garcia, and Aleksandr Pankov, and Chibo Hong, and Pia Eriksson, and Joseph F Costello, and Russell O Pieper, and Sabrina M Ronen
August 2012, Oncotarget,
Copied contents to your clipboard!